Cipher Pharmaceuticals (TSE:CPH) Raised to Buy at Stifel Nicolaus

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) was upgraded by equities research analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating in a report issued on Tuesday, BayStreet.CA reports. The brokerage presently has a C$16.00 price objective on the stock, up from their previous price objective of C$9.50. Stifel Nicolaus’ target price suggests a potential upside of 14.70% from the stock’s previous close.

Cipher Pharmaceuticals Price Performance

Shares of TSE CPH traded up C$0.51 during midday trading on Tuesday, hitting C$13.95. 35,847 shares of the company’s stock were exchanged, compared to its average volume of 36,244. Cipher Pharmaceuticals has a 12-month low of C$3.45 and a 12-month high of C$14.55. The company has a current ratio of 7.96, a quick ratio of 2.67 and a debt-to-equity ratio of 0.38. The company has a market cap of C$336.33 million, a price-to-earnings ratio of 11.34 and a beta of 1.05. The business’s fifty day moving average price is C$9.42 and its two-hundred day moving average price is C$8.53.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.